Intestinal mucosal injury
Conditions
Interventions
Sponsors
Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Adult patients aged 18-80 years; (2) Agree to comply with all research procedures; (3) Provide written informed consent; (4) Capsule endoscopy was successfully completed (the entire upper digestive tract and small intestine were visible) without ulceration or active bleeding (erosion allowed); (5) Have not used anticoagulants or non-steroidal anti-inflammatory drugs before, use low-dose aspirin 100 mg/ time, once a day for the first time; Aspirin of the same regimen was continued during the observation period of this study.
Exclusion criteria
Exclusion criteria: (1) Use non-steroidal anti-inflammatory drugs or anticoagulants other than aspirin; (2) Subjects using other mucosal protective agents, acid suppressors, antibiotics, thyroxine sodium and other drugs; (3) have active gastrointestinal bleeding or ulcers, or have had gastrointestinal bleeding or ulcers within the past 24 months; Have a history of gastrointestinal or abdominal surgery, except for simple procedures such as polypectomy, cholecystectomy or appendectomy that do not change the gastrointestinal anatomy; (4) Contraindications for capsule endoscopy, including suspected or known gastrointestinal obstruction, stenosis, fistula, diverticulum, etc.; Symptoms of gastrointestinal obstruction, such as pain or difficulty swallowing; Poor surgical conditions or refusal to perform abdominal surgery when needed (i.e. if the capsule does not pass and cannot be removed by endoscope); (5) severe liver and kidney dysfunction, cardiopulmonary dysfunction; (6) Subjects who became pregnant or wished to become pregnant during the study period; (7) Subjects whose cecum could not be reached by capsule endoscopy; (8) Hemoglobin < 100g/L, platelet count <100 × 10^9/L; (9) any conditions that may interfere with any study procedure, such as dementia, mobility problems, alcohol consumption, etc.; (10) any comorbidities with an estimated survival time <12 months (e.g. progressive cancer, chronic obstructive pulmonary disease, etc.); (11) Participation in any other investigational drug or device that does not meet its primary endpoint.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of small intestinal mucosal lesions;intestinal flora; | — |
Secondary
| Measure | Time frame |
|---|---|
| hemoglobin;Fecal occult blood test; | — |
Countries
China
Contacts
Public ContactMei Liu
Tongji Medical College, Huazhong University of Science and Technology; Department of Gastroenterology,Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed